Page 42 - Read Online

Genvigir et al. J Transl Genet Genom 2020;4:320-55 I http://dx.doi.org/10.20517/jtgg.2020.37 Page 327

Ref. [34] [40] [37] [41] [29] [35] [27] [38]

Clinical outcomes UGT1A8 c.518G allele was associated with low risk of diarrhea, on cyclosporine treatment - - UGT1A8 c.518GG genotype was associated with higher gastrointestinal symptom rating scale (GSRS) score up two weeks No association of UGT1A8 c.518C>G variant with AR or adverse events - No association of UGT1A8*2 and UGT1A8*3 variants with leukopenia -

Pharmacokinetics No association of UGT1A8 c.830G>A variant with MPA pharmacokinetics No association of UGT1A8 c.518C>G variant with MPA or MPAG exposure (AUC 4-12 UGT1A8 c.518G allele was associated with lower MPAG AUC 0-12 No association of UGT1A8 c.518C>G variant with MPA C/D

- or AUC 0-12 ) - - - (days 3-8)
Immunosuppressive regimen MMF Cyclosporine Tacrolimus Sirolimus Up to 115-month follow- up MMF Cyclosporine Tacrolimus Corticosteroids Sixty-day follow-up MMF Cyclosporine Corticosteroids MMF EC-MPS Cyclosporine Tacrolimus Corticosteroids Six-month follow-up EC-MPS Cyclosporine Corticosteroids Six-month follow-up MMF Tacrolimus Corticosteroids MMF Cyclosporine Tacrolimus Sirolimus Corticosteroids One-year follow-up MMF Cy

Population 256 adult patients (France) 89 pediatric patients (France) 37 adult patients (China) 109 adult patients (USA) 189 adult patients (France) 127 adult patients (China) 284 pediatric and young adult patients (USA) 408 adult patients (China)

Study design Retrospective Prospective, multicenter Prospective, Multicenter (Case-control) Prospective Prospective, multicenter (Dominos study) Prospective Retrospective (Case- Control), multicenter Retrospective

Allele frequency c.518G: 23% c.830A: 2% c.830A: 1% c.518G: 43% c.518G: 32% c.518G: 25% c.518G: 52% - c.518G: 49%

Variant

Gene